We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cancer Drug Holds Promise as Therapy for Glioblastoma
News

Cancer Drug Holds Promise as Therapy for Glioblastoma

Cancer Drug Holds Promise as Therapy for Glioblastoma
News

Cancer Drug Holds Promise as Therapy for Glioblastoma

The Ivy Center features personalized brain tumor therapies designed to identify promising new strategies within an accelerated timeline. Credit: Ivy Brain Tumor Center
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cancer Drug Holds Promise as Therapy for Glioblastoma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma. The agent, recently approved by the FDA for advanced breast cancer, is part of a newly-discovered class of targeted therapy that undermines cancer cell division and could form the backbone of a new drug cocktail for patients with malignant brain tumors like glioblastoma.

"Glioblastoma presents singular, complex challenges as compared to other types of cancer," said Dr. Nader Sanai, director of the Ivy Brain Tumor Center. "You are not dealing with a single entity, but rather a collection of genetic variants that differ from patient to patient. This Phase 0 clinical trial used a precision medicine approach to uncover which subtypes of glioblastoma may respond to ribociclib and how our patients' tumors developed resistance to the new therapy."

Results from the trial show that ribociclib is uniquely capable of breaking through the blood-brain barrier, a critical obstacle that for years has stalled drug development in brain tumor patients, and that the drug effectively hits its molecular target in cancer cells. The experimental Phase 0 clinical trial design also identifies a potential mechanism of drug resistance, which the Ivy Brain Tumor Center clinical trials team is now exploiting as part of an ongoing drug cocktail trial for recurrent glioblastoma patients.

"This comprehensive study has helped us to identify a potent combined-drug regimen to undermine a glioblastoma resistance mechanism to ribociclib. In less than a year, we have made tremendous progress in moving towards creating a new drug cocktail, which is significant given how precious time is for both patients and physicians fighting this disease," said Dr. Sanai.

Reference: An-Chi Tien, et al. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. Clinical Cancer Research (2019) DOI: 10.1158/1078-0432.CCR-19-0133

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement